In fact, most currently approved first- and second-line therapies for advanced HCC target angiogenic pathways, in which the VEGF/VEGF receptor (VEGFR) signaling pathway has been validated as a therapeutic target in HCC [85]. The gene discussed is KDR; the disease is hepatocellular carcinoma.